TY - JOUR
KW - Alzheimer Disease/drug therapy/economics
KW - Antidepressive Agents/adverse effects/economics/therapeutic use
KW - Antipsychotic Agents/adverse effects/economics/therapeutic use
KW - Cost-Benefit Analysis
KW - Depressive Disorder, Major/drug therapy/economics
KW - Drug Costs/statistics & numerical data
KW - Evidence-Based Medicine/economics
KW - Health Policy/economics
KW - Humans
KW - Insurance Coverage
KW - Insurance, Pharmaceutical Services
KW - Mental Disorders/drug therapy/economics
KW - Psychotic Disorders/drug therapy/economics
KW - Psychotropic Drugs/economics/therapeutic use
KW - Randomized Controlled Trials as Topic
KW - Schizophrenia/drug therapy/economics
KW - Treatment Outcome
KW - United States
AU - P. S. Wang
AU - C. M. Ulbricht
AU - M. Schoenbaum
A1 - 
AB - There is a pressing need for comparative effectiveness research to improve mental health treatments. Although U.S. mental health spending has increased dramatically, mainly because of the rapid adoption of newer psychotropic medications, fewer than a quarter of people with serious mental illnesses receive appropriate care. Because of a general lack of information on the relative effectiveness of different treatments, payers are uncertain about the value of current spending, which in turn may deter new investments to reduce unmet need. We use several recent comparative effectiveness trials to illustrate the potential value of such research for improving practice and policy.
BT - Health affairs (Project Hope)
C5 - Financing & Sustainability; Key & Foundational
CP - 3
CY - United States
DO - 10.1377/hlthaff.28.3.783
IS - 3
JF - Health affairs (Project Hope)
N2 - There is a pressing need for comparative effectiveness research to improve mental health treatments. Although U.S. mental health spending has increased dramatically, mainly because of the rapid adoption of newer psychotropic medications, fewer than a quarter of people with serious mental illnesses receive appropriate care. Because of a general lack of information on the relative effectiveness of different treatments, payers are uncertain about the value of current spending, which in turn may deter new investments to reduce unmet need. We use several recent comparative effectiveness trials to illustrate the potential value of such research for improving practice and policy.
PP - United States
PY - 2009
SN - 1544-5208; 0278-2715
SP - 783
EP - 791
EP - 
T1 - Improving mental health treatments through comparative effectiveness research
T2 - Health affairs (Project Hope)
TI - Improving mental health treatments through comparative effectiveness research
U1 - Financing & Sustainability; Key & Foundational
U2 - 19414887
U3 - 10.1377/hlthaff.28.3.783
VL - 28
VO - 1544-5208; 0278-2715
Y1 - 2009
ER -